中新网上海3月20日电（陈静 李东）淋巴瘤是一种起源于淋巴造血系统的恶性肿瘤，是近百种不同亚型“淋巴瘤家族”的统称。复发和耐药是患者面临的一大问题。然而，随着医学技术的不断进步，CAR-T细胞疗法作为一种全新的治疗手段，为这些难治性淋巴瘤患者带来了新的曙光。
CAR-T细胞疗法是一种个体化定制的免疫疗法，它通过从患者体内提取并改造其自身的T细胞，使其能够特异性地识别和攻击肿瘤细胞。这些改造后的T细胞被重新注入患者体内，继续它们的抗癌任务。目前，该疗法已在复发难治性淋巴瘤患者中展现出显著的治疗效果，甚至有患者实现了长期缓解乃至治愈。
上海的研究团队在CAR-T细胞疗法的研发和应用上取得了重要进展。他们针对不同亚型的淋巴瘤，设计了多种CAR-T细胞疗法，并在临床治疗中取得了积极成果。这些研究成果为难治性淋巴瘤患者带来了新的治疗选择，也为未来肿瘤治疗的发展指明了方向。
英文翻译内容：
Title: CAR-T Cell Therapy Offers Hope for Curing Relapsed or Refractory Lymphoma
Keywords: CAR-T Therapy, Lymphoma Treatment, Cure Hope
News content:
SHANGHAI, March 20 (Xinhua) — Lymphoma, a type of malignant tumor originating from the lymphatic and hematopoietic systems, encompasses nearly 100 different subtypes known as the “lymphoma family.” One of the major challenges faced by patients is tumor recurrence and drug resistance.
However, with the continuous advancement of medical technology, CAR-T cell therapy, a novel treatment approach, has brought new hope to these patients with relapsed or refractory lymphoma.
CAR-T cell therapy is a personalized immunotherapy that involves extracting T cells from a patient’s body, modifying them to specifically recognize and attack tumor cells, and then reinfusing them back into the patient. These engineered T cells continue their anti-cancer mission within the patient’s body. The therapy has demonstrated significant therapeutic effects in patients with relapsed or refractory lymphoma, with some achieving long-term remission or even cure.
Research teams in Shanghai have made significant progress in the development and application of CAR-T cell therapy. They have designed various CAR-T cell therapies targeting different subtypes of lymphoma and have achieved positive results in clinical treatment. These research findings provide new treatment options for patients with relapsed or refractory lymphoma and point the way forward for the development of cancer treatment.
【来源】http://www.chinanews.com/life/2024/03-20/10183873.shtml
Views: 1